Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Red Light · 1 trial · 1 indication
Adverse events and local tolerability assessed at pre and immediately post treatment, at Day 1 and Day 7 following treatment.
| Arm | Type | Description |
|---|---|---|
| Red light dose (PDT) 75 J/cm2 | OTHER | Subjects in Cohort 1 will receive active and vehicle solution followed by a red light dose of 75 J/cm2 at 25 mW/cm2 |
| Red Light (PDT) 150 J/cm2 | OTHER | Subjects in Cohort 2 will receive active and vehicle solution followed by a red light dose of 150 J/cm2 at 40 mW/cm2 |
| Name | Type | Description |
|---|---|---|
| Red Light (PDT) | DRUG | LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2) |
Inclusion Criteria: 1. Healthy adults 18 years of age or older 2. Fitzpatrick skin types I-IV Exclusion Criteria: 1. Current pregnancy or lactation. 2. Presence of severe facial acne, acne fulminans or conglobata, or nodulocystic acne. 3. Poor skin condition on the back, including erythema, dryne...
Red Light is an investigational small molecule being developed by Eli Lilly and Company for the treatment of Acne Vulgaris. It is currently in Phase 1 clinical development, meaning it is still being tested in early-stage trials to evaluate its safety and tolerability in humans.
Red Light is a small molecule being developed for Acne Vulgaris. The specific molecular target of Red Light has not been disclosed in the available information, so its precise mechanism of action is not publicly known.
Red Light is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical development for the treatment of Acne Vulgaris.
Red Light is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and tolerability in humans.
Red Light has one completed clinical trial, NCT01830764, titled 'Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers.' This Phase 1 study enrolled 12 participants in the United States and was conducted in healthy volunteers aged 18 years and older.
Red Light is associated with the clinical trial identifier LTS-PDT, as seen in the study title 'Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers.' This suggests that LTS-PDT may be an alternative name or formulation of Red Light, though the relationship is not explicitly defined.